PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.25
D/E ratio exceeding 1.5x Biotechnology median of 0.00. Howard Marks would check for debt covenant compliance and refinancing risks.
1.73
Higher net debt at 1.1-1.25x Biotechnology median of 1.42. John Neff would demand higher growth rates to justify this leverage premium.
No Data
No Data available this quarter, please select a different quarter.
1.89
Current ratio below 50% of Biotechnology median of 4.13. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.